Year-end Sale % OFF 
Abstract
Colorectal cancer (CRC) is the leading cause of cancer-related death worldwide. Rectal cancer constitutes around one-third of all CRCs. The current standard of care of patients with locally advanced rectal cancer is neoadjuvant radio/chemo-radiotherapy; however, treatment differs substantially across countries. Novel markers are required to optimize the treatment. Extramural vascular invasion (EMVI) is a well-established magnetic resonance imaging (MRI)-based negative prognostic marker. Systemic inflammatory response markers such as lymphocyte-to-monocyte ratio (LMR), neutrophil-to-lymphocyte ratio (NLR) or platelet-to-lymphocyte ratio (PLR) are novel blood-based prognostic markers in many cancers, including CRC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
